1. Home
  2. DECK vs BBIO Comparison

DECK vs BBIO Comparison

Compare DECK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deckers Outdoor Corporation

DECK

Deckers Outdoor Corporation

HOLD

Current Price

$96.88

Market Cap

14.2B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$80.09

Market Cap

15.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DECK
BBIO
Founded
1973
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2B
15.9B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
DECK
BBIO
Price
$96.88
$80.09
Analyst Decision
Buy
Strong Buy
Analyst Count
23
25
Target Price
$122.45
$86.33
AVG Volume (30 Days)
2.2M
3.2M
Earning Date
05-21-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
10.90
N/A
EPS
0.94
N/A
Revenue
$5,472,296,000.00
$502,076,000.00
Revenue This Year
$11.16
$89.45
Revenue Next Year
$6.96
$73.78
P/E Ratio
$14.19
N/A
Revenue Growth
9.76
126.26
52 Week Low
$78.91
$42.09
52 Week High
$125.45
$93.42

Technical Indicators

Market Signals
Indicator
DECK
BBIO
Relative Strength Index (RSI) 42.05 49.57
Support Level $97.84 $78.98
Resistance Level $106.11 $81.33
Average True Range (ATR) 3.68 2.48
MACD -0.36 -0.68
Stochastic Oscillator 35.81 7.70

Price Performance

Historical Comparison
DECK
BBIO

About DECK Deckers Outdoor Corporation

Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: